This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT), announced today that a poster describing the ongoing SNS01-T study in multiple myeloma will be presented at the 2012 Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2012 in Chicago, Illinois. The abstract will be presented by Dr. John Lust, the principal investigator from the Mayo Clinic, Rochester, Minnesota.
Poster Discussion Session at ASCO, Chicago, IL (June 1-5, 2012)
Date/Time: Monday, June 4, 2012; 1:15 PM — 5:15 PM (CT)
Location: S Hall A2, Poster Board #41A
Abstract #TPS8116: Phase 1b/2a open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01-T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma. Dr. John Lust et al. the Mayo Clinic, Rochester, Minnesota
SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of a Phase 1b/2a open-label, multiple-dose, dose-escalation study which will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients. The study is actively enrolling patients at the Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, and the Mary Babb Randolph Cancer Center in Morgantown, West Virginia.
http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1About Multiple Myeloma
Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies, in which abnormal cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal blood cells. Senesco was previously granted orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of multiple myeloma.